(Q36672697)

15 August 2017

1 reference

title

Drug insight: Existing and emerging therapies for osteoporosis (English)

1 reference

15 August 2017

Jean E Mulder

1

1 reference

15 August 2017

Nikheel S Kolatkar

series ordinal

2

1 reference

15 August 2017

Meryl S LeBoff

series ordinal

3

1 reference

15 August 2017

language of work or name

1 reference

1 December 2006

1 reference

Nature Clinical Practice Endocrinology and Metabolism

15 August 2017

published in

1 reference

15 August 2017

volume

2

1 reference

15 August 2017

issue

12

1 reference

15 August 2017

page(s)

670-680

1 reference

Prevalence of Vitamin D inadequacy among postmenopausal North American women receiving osteoporosis therapy

15 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1038%2FNCPENDMET0325

Occult vitamin D deficiency in postmenopausal US women with acute hip fracture

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPENDMET0325

Hypovitaminosis D in Medical Inpatients

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPENDMET0325

Vitamin D3 and calcium to prevent hip fractures in elderly women

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPENDMET0325

Effect of calcium and vitamin D supplementation on bone density in men and women 65 years of age or older

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPENDMET0325

Effect of four monthly oral vitamin D3 (cholecalciferol) supplementation on fractures and mortality in men and women living in the community: randomised double blind controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPENDMET0325

Role of supplemental calcium in the recurrence of colorectal adenomas: a metaanalysis of randomized controlled trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPENDMET0325

Estimates of optimal vitamin D status

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPENDMET0325

Calcium plus vitamin D supplementation and the risk of fractures

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPENDMET0325

Oral vitamin D3 and calcium for secondary prevention of low-trauma fractures in elderly people (Randomised Evaluation of Calcium Or vitamin D, RECORD): a randomised placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPENDMET0325

Randomized comparison of the effects of the vitamin D3 adequate intake versus 100 mcg (4000 IU) per day on biochemical responses and the wellbeing of patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPENDMET0325

Assay variation confounds the diagnosis of hypovitaminosis D: a call for standardization

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPENDMET0325

Ovarian steroid treatment blocks a postmenopausal increase in blood monocyte interleukin 1 release

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPENDMET0325

Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results From the Women's Health Initiative randomized controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPENDMET0325

Effects of ultralow-dose transdermal estradiol on bone mineral density: a randomized clinical trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPENDMET0325

Two to three years of hormone replacement treatment in healthy women have long-term preventive effects on bone mass and osteoporotic fractures: the PERF study

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPENDMET0325

From molds and macrophages to mevalonate: a decade of progress in understanding the molecular mode of action of bisphosphonates.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPENDMET0325

Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures. Fracture Intervention Trial Research Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPENDMET0325

Effect of alendronate on risk of fracture in women with low bone density but without vertebral fractures: results from the Fracture Intervention Trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPENDMET0325

Effect of oral alendronate on bone mineral density and the incidence of fractures in postmenopausal osteoporosis. The Alendronate Phase III Osteoporosis Treatment Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPENDMET0325

Alendronate for the Treatment of Osteoporosis in Men

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPENDMET0325

Two-year effects of alendronate on bone mineral density and vertebral fracture in patients receiving glucocorticoids: a randomized, double-blind, placebo-controlled extension trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPENDMET0325

Prevention of bone loss with alendronate in postmenopausal women under 60 years of age. Early Postmenopausal Intervention Cohort Study Group.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPENDMET0325

Two-year results of once-weekly administration of alendronate 70 mg for the treatment of postmenopausal osteoporosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPENDMET0325

Ten years' experience with alendronate for osteoporosis in postmenopausal women

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPENDMET0325

Histomorphometric assessment of the long-term effects of alendronate on bone quality and remodeling in patients with osteoporosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPENDMET0325

Randomized trial of effect of alendronate continuation versus discontinuation in women with low BMD: results from the Fracture Intervention Trial long-term extension

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPENDMET0325

Effects of risedronate treatment on vertebral and nonvertebral fractures in women with postmenopausal osteoporosis: a randomized controlled trial. Vertebral Efficacy With Risedronate Therapy (VERT) Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPENDMET0325

Effect of risedronate on the risk of hip fracture in elderly women. Hip Intervention Program Study Group.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPENDMET0325

Randomized trial of the effects of risedronate on vertebral fractures in women with established postmenopausal osteoporosis. Vertebral Efficacy with Risedronate Therapy (VERT) Study Group.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPENDMET0325

The efficacy and tolerability of risedronate once a week for the treatment of postmenopausal osteoporosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPENDMET0325

Seven years of treatment with risedronate in women with postmenopausal osteoporosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPENDMET0325

Treatment with once-weekly alendronate 70 mg compared with once-weekly risedronate 35 mg in women with postmenopausal osteoporosis: a randomized double-blind study

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPENDMET0325

Clinical practice. Postmenopausal osteoporosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPENDMET0325

Effects of oral ibandronate administered daily or intermittently on fracture risk in postmenopausal osteoporosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPENDMET0325

The effect of intravenous pamidronate versus oral alendronate on bone mineral density in patients with osteoporosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPENDMET0325

Intravenous zoledronic acid in postmenopausal women with low bone mineral density

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPENDMET0325

Narrative [corrected] review: bisphosphonates and osteonecrosis of the jaws

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPENDMET0325

Effect of parathyroid hormone (1-34) on fractures and bone mineral density in postmenopausal women with osteoporosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPENDMET0325

The effect of teriparatide [human parathyroid hormone (1-34)] therapy on bone density in men with osteoporosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPENDMET0325

Parathyroid hormone treatment can reverse corticosteroid-induced osteoporosis. Results of a randomized controlled clinical trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPENDMET0325

A randomized double-blind trial to compare the efficacy of teriparatide [recombinant human parathyroid hormone (1-34)] with alendronate in postmenopausal women with osteoporosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPENDMET0325

Daily and cyclic parathyroid hormone in women receiving alendronate

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPENDMET0325

Recombinant Human Parathyroid Hormone (1–34) [Teriparatide] Improves Both Cortical and Cancellous Bone Structure

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPENDMET0325

Parathyroid hormone and teriparatide for the treatment of osteoporosis: a review of the evidence and suggested guidelines for its use.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPENDMET0325

Reduction of vertebral fracture risk in postmenopausal women with osteoporosis treated with raloxifene: results from a 3-year randomized clinical trial. Multiple Outcomes of Raloxifene Evaluation (MORE) Investigators

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPENDMET0325

Efficacy of raloxifene on vertebral fracture risk reduction in postmenopausal women with osteoporosis: four-year results from a randomized clinical trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPENDMET0325

Skeletal effects of raloxifene after 8 years: results from the continuing outcomes relevant to Evista (CORE) study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPENDMET0325

Safety and efficacy of a novel salmon calcitonin (sCT) technology-based oral formulation in healthy postmenopausal women: acute and 3-month effects on biomarkers of bone turnover

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPENDMET0325

The effects of parathyroid hormone and alendronate alone or in combination in postmenopausal osteoporosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPENDMET0325

The Effects of Parathyroid Hormone, Alendronate, or Both in Men with Osteoporosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPENDMET0325

Combination teriparatide and raloxifene therapy for postmenopausal osteoporosis: results from a 6-month double-blind placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPENDMET0325

Incorporation and distribution of strontium in bone

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPENDMET0325

The divalent strontium salt S12911 enhances bone cell replication and bone formation in vitro

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPENDMET0325

In vitro effects of S12911-2 on osteoclast function and bone marrow macrophage differentiation

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPENDMET0325

An uncoupling agent containing strontium prevents bone loss by depressing bone resorption and maintaining bone formation in estrogen-deficient rats.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPENDMET0325

Influence of strontium on bone mineral density and bone mineral content measurements by dual X-ray absorptiometry

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPENDMET0325

The effects of strontium ranelate on the risk of vertebral fracture in women with postmenopausal osteoporosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPENDMET0325

Strontium ranelate reduces the risk of nonvertebral fractures in postmenopausal women with osteoporosis: Treatment of Peripheral Osteoporosis (TROPOS) study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPENDMET0325

The effect of a single dose of osteoprotegerin in postmenopausal women

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPENDMET0325

Denosumab in postmenopausal women with low bone mineral density

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPENDMET0325

A novel calcium-sensing receptor antagonist transiently stimulates parathyroid hormone secretion in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPENDMET0325

Design of potent, selective, and orally bioavailable inhibitors of cysteine protease cathepsin k.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPENDMET0325

Effects of conjugated equine estrogen in postmenopausal women with hysterectomy: the Women's Health Initiative randomized controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPENDMET0325

The WHI estrogen-alone trial--do things look any better?

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPENDMET0325

Osteoporosis and vitamin-D deficiency among postmenopausal women with osteoarthritis undergoing total hip arthroplasty

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPENDMET0325

7 January 2021

Human serum 25-hydroxycholecalciferol response to extended oral dosing with cholecalciferol

1 reference

https://api.crossref.org/works/10.1038%2FNCPENDMET0325

7 January 2021

Cytokines, hematopoiesis, osteoclastogenesis, and estrogens

1 reference

https://api.crossref.org/works/10.1038%2FNCPENDMET0325

7 January 2021

Alendronate increases bone strength by increasing the mean degree of mineralization of bone tissue in osteoporotic women

1 reference

https://api.crossref.org/works/10.1038%2FNCPENDMET0325

7 January 2021

Long-term safety of bisphosphonates

1 reference

https://api.crossref.org/works/10.1038%2FNCPENDMET0325

7 January 2021

Risedronate therapy prevents corticosteroid-induced bone loss: a twelve-month, multicenter, randomized, double-blind, placebo-controlled, parallel-group study

1 reference

https://api.crossref.org/works/10.1038%2FNCPENDMET0325

7 January 2021

Randomised controlled study of effect of parathyroid hormone on vertebral-bone mass and fracture incidence among postmenopausal women on oestrogen with osteoporosis

1 reference

https://api.crossref.org/works/10.1038%2FNCPENDMET0325

7 January 2021

Efficacy and Safety of Human Parathyroid Hormone-(1–84) in Increasing Bone Mineral Density in Postmenopausal Osteoporosis

1 reference

https://api.crossref.org/works/10.1038%2FNCPENDMET0325

7 January 2021

Effects of daily treatment with parathyroid hormone on bone microarchitecture and turnover in patients with osteoporosis: a paired biopsy study

1 reference

https://api.crossref.org/works/10.1038%2FNCPENDMET0325

7 January 2021

Effects of teriparatide [recombinant human parathyroid hormone (1-34)] on cortical bone in postmenopausal women with osteoporosis

1 reference

https://api.crossref.org/works/10.1038%2FNCPENDMET0325

7 January 2021

Short-term, high-dose parathyroid hormone-related protein as a skeletal anabolic agent for the treatment of postmenopausal osteoporosis

1 reference

https://api.crossref.org/works/10.1038%2FNCPENDMET0325

7 January 2021

Skeletal changes in rats given daily subcutaneous injections of recombinant human parathyroid hormone (1-34) for 2 years and relevance to human safety

1 reference

https://api.crossref.org/works/10.1038%2FNCPENDMET0325

7 January 2021

A randomized trial of nasal spray salmon calcitonin in postmenopausal women with established osteoporosis: the prevent recurrence of osteoporotic fractures study. PROOF Study Group

1 reference

https://api.crossref.org/works/10.1038%2FNCPENDMET0325

7 January 2021

The importance of bisphosphonate therapy in maintaining bone mass in men after therapy with teriparatide [human parathyroid hormone(1-34)]

1 reference

https://api.crossref.org/works/10.1038%2FNCPENDMET0325

7 January 2021

Recombinant osteoprotegerin for juvenile Paget's disease

1 reference

https://api.crossref.org/works/10.1038%2FNCPENDMET0325

7 January 2021

Effect of L-000845704, an alphaVbeta3 integrin antagonist, on markers of bone turnover and bone mineral density in postmenopausal osteoporotic women

1 reference

https://api.crossref.org/works/10.1038%2FNCPENDMET0325

7 January 2021

Identifiers

DOI

10.1038/NCPENDMET0325

1 reference

15 August 2017

1 reference